Eris Lifesciences acquires 51% stake in Swiss Parenterals

16 Feb 2024 Evaluate

Eris Lifesciences has completed acquisition of 51% equity stake in Swiss Parenterals. On February 13, 2024, the company had executed Share Purchase and Shareholders’ agreement for acquisition of 51% equity stake in Swiss Parenterals. The cost of acquisition is Rs 637.50 crore. 

Eris Lifesciences develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives.

Eris Lifesciences Share Price

884.70 -9.95 (-1.11%)
30-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1502.30
Dr. Reddys Lab 6198.90
Cipla 1402.20
Zydus Lifesciences 957.00
Lupin 1645.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.